Analysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) Price Target at $38.00

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fourteen analysts that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $38.00.

DNLI has been the topic of a number of recent research reports. HC Wainwright dropped their price target on shares of Denali Therapeutics from $90.00 to $87.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Robert W. Baird started coverage on Denali Therapeutics in a research report on Tuesday, January 7th. They set an "outperform" rating and a $31.00 target price on the stock. The Goldman Sachs Group cut their price target on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Baird R W upgraded Denali Therapeutics to a "strong-buy" rating in a research note on Tuesday, January 7th. Finally, William Blair restated an "outperform" rating on shares of Denali Therapeutics in a research note on Wednesday, January 15th.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI traded down $0.28 during trading on Tuesday, reaching $22.25. 817,231 shares of the stock traded hands, compared to its average volume of 1,014,313. The stock has a market capitalization of $3.20 billion, a P/E ratio of -8.06 and a beta of 1.43. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $33.33. The company has a 50-day moving average of $22.25 and a 200-day moving average of $24.83.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the firm earned ($0.72) EPS. Analysts expect that Denali Therapeutics will post -2.74 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other news, Director Vicki L. Sato sold 3,080 shares of the company's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the transaction, the director now directly owns 107,976 shares in the company, valued at approximately $2,257,778.16. This represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ryan J. Watts sold 29,266 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the transaction, the chief executive officer now owns 260,721 shares in the company, valued at $5,271,778.62. This trade represents a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,940 shares of company stock valued at $973,442. 7.90% of the stock is owned by corporate insiders.

Institutional Trading of Denali Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. CWM LLC lifted its holdings in shares of Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company's stock worth $63,000 after acquiring an additional 654 shares during the last quarter. Quest Partners LLC purchased a new position in Denali Therapeutics in the 3rd quarter worth $73,000. PNC Financial Services Group Inc. lifted its stake in Denali Therapeutics by 30.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after purchasing an additional 885 shares during the last quarter. Assetmark Inc. boosted its position in Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company's stock valued at $111,000 after buying an additional 580 shares during the period. Finally, KBC Group NV grew its stake in shares of Denali Therapeutics by 75.8% during the fourth quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after buying an additional 2,731 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.